• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Agilent Acquires Sigsense, Creator of AI-Enabled Lab Operations Technology

    7/29/24 9:55:00 AM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $A alert in real time by email

    Technology helps high-throughput labs operate more efficiently

    Agilent Technologies Inc. (NYSE:A) today announced it has acquired Sigsense Technologies, a San Francisco, California-based startup that uses artificial intelligence and power monitoring to help optimize lab operations. Financial terms of the acquisition were not disclosed.

    Sigsense technology is already available to Agilent customers through CrossLab Connect, a suite of digital applications—inventory management, service management, asset monitoring, smart alerts, and asset lifecycle analytics—that improve lab performance.

    Integrated into the Agilent CrossLab Connect asset monitoring solution, Sigsense's algorithm tracks instrument utilization and status across all scientific assets, regardless of vendor or manufacturer. The operational insights collected from the technology alert lab managers of assets that are underperforming and how to optimize them.

    "We are excited to welcome the Sigsense team to Agilent. They are an innovator in leveraging artificial intelligence for lab operations," said Armin Jehle, vice president, Agilent CrossLab Services Division. "By working closely as one team, we will extend their AI technology further, enabling more customers to gain more insights that contribute to reduced downtime and increased productivity."

    Asset monitoring is particularly important for commercial labs with large instrument fleets, intense testing schedules, and quick turnaround times.

    CrossLab Connect monitors a wide range of instruments, including chromatography, mass spectrometry, spectroscopy, liquid handlers and plate readers, flow cytometry, centrifuges, NMR, sequencers, PCR, and more.

    With this transaction, Sigsense employees, IP, and assets are now part of the Agilent CrossLab Group. Additional information for customers of Sigsense is available here.

    About CrossLab Connect

    CrossLab Connect is a digital suite of laboratory applications and sensor technologies that accelerate laboratory performance with wide-ranging visibility and control over a lab's instrument fleet. The comprehensive view of operations provided by CrossLab Connect improves lab planning and optimizes operational spend, while reducing workflow disruption.

    Additional CrossLab Connect Resources

    • CrossLab Connect Digital Applications
      • Asset Monitoring
      • Service Manager
      • Inventory Manager
      • Smart Alerts
      • Asset Lifecycle Analytics
    • Learn how CrossLab Asset Monitoring can inform lab investment decisions (video)
    • Request a demo of CrossLab Connect

    About Agilent Technologies

    Agilent Technologies Inc. (NYSE:A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent's full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. The company generated revenue of $6.83 billion in fiscal 2023 and employs approximately 18,000 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn and Facebook.

    Forward Looking Statements

    This news release contains forward-looking statements as defined in the Securities Exchange Act of 1934 and is subject to the safe harbors created therein. The forward-looking statements contained herein include, but are not limited to, statements regarding the capabilities the acquisition brings and the assets' future uses. These forward-looking statements involve risks and uncertainties that could cause Agilent's results to differ materially from management's current expectations. Such risks and uncertainties include, but are not limited to, unforeseen changes in the strength of Agilent's customers' businesses; unforeseen changes in the demand for current and new products, technologies, and services; unforeseen changes in the currency markets; customer purchasing decisions and timing; and the risk that Agilent is not able to realize the savings expected from integration and restructuring activities. In addition, other risks that Agilent faces in running its operations include the ability to execute successfully through business cycles; the ability to meet and achieve the benefits of its cost-reduction goals and otherwise successfully adapt its cost structures to continuing changes in business conditions; ongoing competitive, pricing and gross-margin pressures; the risk that its cost-cutting initiatives will impair its ability to develop products and remain competitive and to operate effectively; the impact of geopolitical uncertainties and global economic conditions on its operations, its markets and its ability to conduct business; the ability to improve asset performance to adapt to changes in demand; the ability of its supply chain to adapt to changes in demand; the ability to successfully introduce new products at the right time, price and mix; the ability of Agilent to successfully integrate recent acquisitions; the ability of Agilent to successfully comply with certain complex regulations; and other risks detailed in Agilent's filings with the Securities and Exchange Commission, including its quarterly report on Form 10-Q for the fiscal quarter ended April 30, 2024. Forward-looking statements are based on the beliefs and assumptions of Agilent's management and on currently available information. Agilent undertakes no responsibility to publicly update or revise any forward-looking statement.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20240729556289/en/

    Get the next $A alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $A

    DatePrice TargetRatingAnalyst
    2/10/2025$135.00 → $145.00Underweight → Equal Weight
    Barclays
    8/28/2024$157.00Overweight
    Wells Fargo
    7/10/2024$135.00 → $150.00Neutral → Buy
    Citigroup
    6/27/2024Outperform → Peer Perform
    Wolfe Research
    6/3/2024$135.00Hold
    Jefferies
    4/5/2024$145.00 → $163.00Hold → Buy
    Stifel
    12/13/2023$140.00Outperform
    Wolfe Research
    12/12/2023$130.00 → $133.00Buy → Neutral
    BofA Securities
    More analyst ratings

    $A
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Agilent upgraded by Barclays with a new price target

    Barclays upgraded Agilent from Underweight to Equal Weight and set a new price target of $145.00 from $135.00 previously

    2/10/25 6:55:03 AM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Wells Fargo initiated coverage on Agilent with a new price target

    Wells Fargo initiated coverage of Agilent with a rating of Overweight and set a new price target of $157.00

    8/28/24 7:20:29 AM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Agilent upgraded by Citigroup with a new price target

    Citigroup upgraded Agilent from Neutral to Buy and set a new price target of $150.00 from $135.00 previously

    7/10/24 7:22:08 AM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $A
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Gonsalves Rodney (Amendment)

    4/A - AGILENT TECHNOLOGIES, INC. (0001090872) (Issuer)

    10/20/23 1:07:25 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Gonsalves Rodney bought $288 worth of shares (3 units at $111.09), increasing direct ownership by 0.01% to 24,222 units (SEC Form 4)

    4 - AGILENT TECHNOLOGIES, INC. (0001090872) (Issuer)

    9/29/23 4:03:46 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $A
    SEC Filings

    View All

    SEC Form 10-Q filed by Agilent Technologies Inc.

    10-Q - AGILENT TECHNOLOGIES, INC. (0001090872) (Filer)

    8/29/25 4:33:55 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Agilent Technologies Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - AGILENT TECHNOLOGIES, INC. (0001090872) (Filer)

    8/27/25 4:06:24 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Amendment: Agilent Technologies Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K/A - AGILENT TECHNOLOGIES, INC. (0001090872) (Filer)

    8/8/25 4:15:28 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $A
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Agilent Announces New Insight Series Alarm Resolution Systems for Airport Security Screening

    Next-generation explosive detection systems deliver unmatched accuracy, speed, and adaptability for evolving airport security needs Agilent Technologies Inc. (NYSE:A) today announced the launch of its new Insight Series Alarm Resolution Systems, designed to enhance safety and streamline operations at airport security checkpoints worldwide. The Insight Series includes the Insight300M and InsightBLS, advanced liquid explosive detection systems (LEDs) that meet global regulations for screening liquids, aerosols, and gels (LAGs). With the industry's lowest false alarm rate and rapid scan times, the Insight Series ensures faster airport passenger flow, reduced operational disruptions, and en

    9/30/25 8:00:00 AM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Agilent Announces Cash Dividend of 24.8 Cents per Share

    Agilent Technologies, Inc. (NYSE:A) today announced a quarterly dividend of 24.8 cents per share of common stock. The quarterly dividend will be paid on Oct. 22, 2025, to all shareholders of record as of the close of business on Sept. 30, 2025. The timing and amounts of future dividends are subject to determination and approval by Agilent's board of directors. About Agilent Technologies Agilent Technologies Inc. (NYSE:A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent's full range of solutions includes instruments, software, services, and expertise that provide truste

    9/17/25 4:05:00 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Aquatech Acquires Koch's Direct Lithium Extraction Business, Integrating Li-Pro™ DLE into the PEARL™ Technology Platform

    CANONSBURG, Pa., Sept. 16, 2025 /PRNewswire/ -- Aquatech has acquired Koch Technology Solutions' (KTS) direct lithium extraction (DLE) business, integrating the Li-Pro™ Lithium Selective Sorption (LSS) technology and extensive Li-Pro IP portfolio into the PEARL™ process technology platform. The acquisition of KTS' Li-Pro LSS technology adds direct lithium extraction to Aquatech's extensive process flowsheet IP, lithium conversion and crystallization capabilities. With this addition, Aquatech's PEARL platform becomes the only commercially proven, end-to-end flowsheet solution f

    9/16/25 5:21:00 PM ET
    $A
    $EQNR
    $SLI
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Integrated oil Companies
    Energy

    $A
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and CEO Mcdonnell Padraig sold $249,760 worth of shares (2,000 units at $124.88), decreasing direct ownership by 6% to 33,448 units (SEC Form 4)

    4 - AGILENT TECHNOLOGIES, INC. (0001090872) (Issuer)

    9/4/25 3:36:26 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    President and CEO Mcdonnell Padraig sold $226,900 worth of shares (2,000 units at $113.45), decreasing direct ownership by 5% to 35,448 units (SEC Form 4)

    4 - AGILENT TECHNOLOGIES, INC. (0001090872) (Issuer)

    8/4/25 4:15:32 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    V.P., Corporate Controller Gonsalves Rodney was granted 9,031 shares, increasing direct ownership by 41% to 30,972 units (SEC Form 4)

    4 - AGILENT TECHNOLOGIES, INC. (0001090872) (Issuer)

    7/18/25 2:43:11 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $A
    Financials

    Live finance-specific insights

    View All

    Agilent Announces Cash Dividend of 24.8 Cents per Share

    Agilent Technologies, Inc. (NYSE:A) today announced a quarterly dividend of 24.8 cents per share of common stock. The quarterly dividend will be paid on Oct. 22, 2025, to all shareholders of record as of the close of business on Sept. 30, 2025. The timing and amounts of future dividends are subject to determination and approval by Agilent's board of directors. About Agilent Technologies Agilent Technologies Inc. (NYSE:A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent's full range of solutions includes instruments, software, services, and expertise that provide truste

    9/17/25 4:05:00 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Aquatech Acquires Koch's Direct Lithium Extraction Business, Integrating Li-Pro™ DLE into the PEARL™ Technology Platform

    CANONSBURG, Pa., Sept. 16, 2025 /PRNewswire/ -- Aquatech has acquired Koch Technology Solutions' (KTS) direct lithium extraction (DLE) business, integrating the Li-Pro™ Lithium Selective Sorption (LSS) technology and extensive Li-Pro IP portfolio into the PEARL™ process technology platform. The acquisition of KTS' Li-Pro LSS technology adds direct lithium extraction to Aquatech's extensive process flowsheet IP, lithium conversion and crystallization capabilities. With this addition, Aquatech's PEARL platform becomes the only commercially proven, end-to-end flowsheet solution f

    9/16/25 5:21:00 PM ET
    $A
    $EQNR
    $SLI
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Integrated oil Companies
    Energy

    Agilent Reports Third-Quarter Fiscal Year 2025 Financial Results

    Agilent delivers strong revenue growth, raises growth outlook  Highlights Revenue of $1.74 billion for the third quarter ended July 31, 2025, exceeding revenue guidance and representing growth of 10.1% reported and up 6.1% on a core(1) basis compared with the third quarter of 2024. GAAP net income of $336 million; earnings per share (EPS) of $1.18, up 22% from the third quarter of 2024. Non-GAAP(2) net income of $390 million; EPS of $1.37, up 4% from the third quarter of 2024. These results reflect a full quarter of the dynamic tariff environment. Outlook for full 2025 fiscal year and Q4 Full-year revenue outlook revised at a range of $6.91 billion to $6.93 billion, repr

    8/27/25 4:05:00 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $A
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    $A
    Leadership Updates

    Live Leadership Updates

    View All

    Amendment: SEC Form SC 13G/A filed by Agilent Technologies Inc.

    SC 13G/A - AGILENT TECHNOLOGIES, INC. (0001090872) (Subject)

    11/12/24 1:27:37 PM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form SC 13G filed by Agilent Technologies Inc.

    SC 13G - AGILENT TECHNOLOGIES, INC. (0001090872) (Subject)

    11/12/24 11:54:03 AM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form SC 13G filed by Agilent Technologies Inc.

    SC 13G - AGILENT TECHNOLOGIES, INC. (0001090872) (Subject)

    11/4/24 10:57:57 AM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Agilent Showcases Solutions and Partnerships Transforming Cancer Research and Therapeutics at AACR 2025

    Agilent Technologies Inc. (NYSE:A) announced today its participation at the American Association for Cancer Research (AACR) Annual Meeting on April 25-30, 2025 in Chicago, Illinois. Innovative Agilent products and partnerships playing a crucial role in transforming cancer research, diagnostics, and therapeutics will be featured, including: Agilent Avida DNA Cancer Panels – Based on cutting-edge next-generation sequencing (NGS) target enrichment solutions that enable simultaneous DNA and methylation profiling from a single sample, the Avida product portfolio has expanded to include three new DNA panels*. Optimized based on the requirements of the European OncNGS Consortium, these catalog p

    4/24/25 8:00:00 AM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Agilent to Acquire North American CDMO BIOVECTRA

    Expands Agilent's end-to-end biopharma solutions that accelerate drug discovery, development, and manufacturing Agilent Technologies Inc. (NYSE:A) today announced it has signed a definitive agreement to acquire BIOVECTRA, a leading specialized contract development and manufacturing organization, for $925 million. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240722078870/en/A BIOVECTRA manufacturing facility (Photo: Business Wire) Based in Canada, BIOVECTRA produces biologics, highly potent active pharmaceutical ingredients, and other molecules for targeted therapeutics. The acquisition builds on Agilent's CDMO specializati

    7/22/24 9:01:00 AM ET
    $A
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Politan Details Why a Truly Independent Board is Urgently Needed at Masimo in Order to Protect Shareholder Value and Realize the Company's Full Potential

    Sends Letter to Masimo Shareholders and Releases 160-Page Investor Presentation Urges Shareholders to Help Deliver Immediate Change by Voting for Both of Politan's Independent and Ideally Qualified Nominees Darlene Solomon and William Jellison on the WHITE Card Shareholders Can Visit www.AdvanceMasimo.com for Further Information Politan Capital Management (together with its affiliates, "Politan"), an 8.9% shareholder of Masimo Corporation ("Masimo" or the "Company") (NASDAQ:MASI), today sent a letter to the Company's shareholders outlining why a majority of truly independent directors are urgently needed in the Masimo boardroom. Politan also released a detailed investor presentation m

    6/26/24 8:00:00 AM ET
    $A
    $ANIK
    $AVNT
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Medical/Dental Instruments
    Health Care